Comprehensive analysis of minoxidil effectiveness for hair growth

Minoxidil is a well-established treatment for androgenetic alopecia. Despite widespread use, variations in individual response and emerging new formulations necessitate a current evidence-based review. To evaluate the effectiveness of minoxidil in various formulations and concentrations, explore genetic influences on treatment response, assess patient-reported outcomes, and summarize recent innovations in delivery systems and combination therapies. A literature review of clinical trials, observational studies, and systematic reviews published between 2000 and 2024 was conducted using PubMed, ScienceDirect, and academic dermatology databases. Studies addressing topical, oral, injectable, and combination minoxidil therapies were included. Topical minoxidil (5%) remains the most effective monotherapy for men, while 2% shows comparable efficacy in women. Genetic markers, particularly SULT1A1 activity, predict treatment response. Foam and gel formulations offer improved tolerability and compliance. Oral low-dose minoxidil shows promise but poses a higher systemic risk. Injectable and combination therapies enhance efficacy in cases of resistance. Long-term use maintains regrowth but may plateau after 12–18 months. Minoxidil continues to be a cornerstone therapy for hair loss. Personalization based on genetic profiling, advanced delivery systems, and adjunct therapies may significantly improve outcomes.